Evidence map›Paper›PMID 18498669›Full record

ReviewInternational psychogeriatrics2008

Developing new treatments for Alzheimer's disease: the who, what, when, and how of biomarker-guided therapies.

Constantine G Lyketsos, Christine A Szekely, Michelle M Mielke, Paul B Rosenberg, Peter P Zandi

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International psychogeriatrics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 29 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Is AD a homogeneous nosologic entity? Yes.Journal of neural transmission (Vienna, Austria : 1996) · 2013
    Article
  7. Article
  8. Article
  9. Article
  10. Neuropsychiatric symptoms in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2011
    Article
  11. Review
  12. Article
  13. Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer's and Parkinson's diseases.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2009
    Review
  14. Improving the quality of life in patients with Alzheimer's disease.Psychiatry (Edgmont (Pa. : Township)) · 2008
    Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Constantine G LyketsosDepartment of Psychiatry and Behavioral Sciences, School of Medicine, Johns Hopkins University, Baltimore, Maryland, U.S.A. kostas@jhmi.edu
Christine A Szekely
Michelle M Mielke
Paul B Rosenberg
Peter P Zandi
Johns Hopkins Bayview Medical Center · USJohns Hopkins University · USCedars-Sinai Medical Center · US

Funding

'T V ASSESSMENT - MEMORY DISORDERED PATIENTS'P50AG005146 · NIA · JOHNS HOPKINS UNIVERSITY · PI BAKKER, ARNOLD · 1985 to 2019
$37.6M
PET imaging of activated microglia in Alzheimer's DiseaseK08AG029157 · NIA · JOHNS HOPKINS UNIVERSITY · PI ROSENBERG, PAUL B · 2008 to 2012
$539k
Blood-based lipid biomarkers reflective of Alzheimer-associated neurodegenerationR21NS060271 · NINDS · JOHNS HOPKINS UNIVERSITY · PI MIELKE, MICHELLE M · 2007 to 2008
$395k
Development of blood lipid biomarkers for Alzheimer's disease progressionR21AG028754 · NIA · JOHNS HOPKINS UNIVERSITY · PI MIELKE, MICHELLE M · 2007 to 2008
$379k
NIA NIH HHS K08 AG029157NIA NIH HHS P50 AG005146NIA NIH HHS P50-AG005146NIA NIH HHS R21 AG028754NIA NIH HHS R21-AG028754NINDS NIH HHS R21 NS060271NINDS NIH HHS R21-NS060271
6 · The paper itself

Abstract

This synthetic review presents an approach to the use of biomarkers for the development of new treatments for Alzheimer's disease (AD). After reviewing the process of translation as applied to AD, the paper provides a general update on what is known about the biology of the disease, and highlights currently available treatments. This is followed by a discussion of future drug development for AD emphasizing the roles that biomarkers are likely to play in this process: (1) define patients who are going to progress rapidly for the purpose of trial enrichment; (2) differentiate disease and therapeutically relevant AD subtypes; (3) assess the potential activity of specific therapies in vivo or ex vivo; and (4) measure the underlying disease state, so as to (a) detect disease and assess drug response in asymptomatic patients, (b) serve as a secondary outcome measure in clinical trials of symptomatic patients, and (c) decide if further development of a treatment should be stopped if not likely to be effective. Several examples are used to illustrate each biomarker utility in the AD context.

Indexed as

Alzheimer DiseaseAniline CompoundsBiomarkersBiomarkers, PharmacologicalBrainCholinesterase InhibitorsClinical Trials as TopicCognition DisordersDisease ProgressionDrug DesignHumansNeuropsychological TestsPlaque, AmyloidPositron-Emission TomographyPsychotropic DrugsRadioligand Assay2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazoleAniline CompoundsBiomarkersBiomarkers, PharmacologicalCholinesterase InhibitorsPsychotropic DrugsThiazoles

Identifiers

PMID18498669
PMCPMC2688723
OpenAlexW2116874258

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.